drugset / Trial / NCT00364429

SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia

NCT00364429

Phase 1 Terminated 55 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This study was designed to compare the \[123\]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients. Investigation of the potential influence of antipsychotic and concomitant medication on \[123I\] CNS 1261 binding is also relevant.Fifteen healthy subjects (male and female of non-child bearing potential) will be recruited and 40 schizophrenic patients divided in 3 subgroups as indicated before: Subgroup a) treatment-naive, (n=10); Subgroup b) on stable treatment with risperidone (without criteria of deficit syndrome on the SDS scale, (n=15);Subgroup c) on stable treatment with risperidone fitting criteria of deficit syndrome on the SDS scale, (n=15).

Timeline

Start
2005-07
Primary completion
2005-07
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified
Subject [123]I-CNS 1261 Unknown
Background Lorazepam Small molecule

Indications